Mastercard (MA)
Verdict history · MA
Every call Verdix has made on MA.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The panel flipped from WAIT to BUY because the addition of The Forensic Skeptic's cautious voice was outweighed by the four bulls converging on the same signal from different frameworks: a 5-year low multiple against peak fundamentals. The previous WAIT reflected a more balanced split when The Macro Opportunist sat in the panel; the current composition tilts decisively toward the view that quality at a reasonable price has finally arrived, though the dissenters keep conviction at MEDIUM rather than HIGH.
See methodology for how verdicts are produced. Full track record →
The panel’s case for MA — and where they disagree.
The case for outweighs the case against at today's price.
NYSE · Financials · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BuyMEDIUM confidence
Why
Mastercard divides the panel into four bulls who see a rare convergence of peak fundamentals and a 5-year-low multiple, and two cautious voices who argue the price is fair rather than cheap. The debate turns on whether the stock's premium multiple is structural or set to mean-revert higher as services revenue expands — and whether patience for a pullback toward the $530–$550 accumulation zone is discipline or missed opportunity.Level to watch
Key resistance 569.38+0.0% from 569.29
Next catalyst
Trigger to confirm the breakout: A weekly close above the all-time high at $601 would resolve the monthly MACD bearish crossover and signal that the uptrend is still in its early innings, not its late ones.The panel's take
Verdict: BUY · Conviction: MED · Last price: 569.29 · Changed from WAIT
What changed since 2026-08-09:
- Price: 562.95 → 569.29 (+1.13%)
- Panel: 2 of 6 → 4 of 6 now Bullish — composition also changed: added The Forensic Skeptic; removed The Macro Opportunist
- Trigger: To SELL: a weekly close below $529.60 (breaking both monthly EMA20 and weekly EMA50, confirming the monthly MACD bearish crossover), OR material US/EU interchange-fee regulation that impairs revenue guidance, OR net margins compressing below 40% signaling the tokenization defense is failing. To raise conviction to HIGH/aggressive BUY: a pullback to $530–$550 (the EMA cluster zone), which would compress the P/E toward 25-27x and provide genuine margin of safety on a wide-moat compounder.
- Verdict: WAIT → BUY
The panel flipped from WAIT to BUY because the addition of The Forensic Skeptic's cautious voice was outweighed by the four bulls converging on the same signal from different frameworks: a 5-year low multiple against peak fundamentals. The previous WAIT reflected a more balanced split when The Macro Opportunist sat in the panel; the current composition tilts decisively toward the view that quality at a reasonable price has finally arrived, though the dissenters keep conviction at MEDIUM rather than HIGH.
The panel divides into four genuine Bulls (fundamental-scout, The Intrinsic-Value Modeler, The GARP Operator, The Scuttlebutt Growth Investor, plus The Quality Rationalist who is bullish but price-sensitive) and two cautious voices. Of the cautious: technical-scout's objection is purely PRICE/TIMING ('great business, wrong entry — wait for $530 or $594'), while The Forensic Skeptic's objection is a mix of BUSINESS/VALUATION (insufficient margin of safety, crowded consensus, but he concedes the business is 'wonderful' and his own DCF at 7% growth yields $580, right at today's price). The BUSINESS objection is thin: The Forensic Skeptic's bear case is a 25x normalized P/E that would still be premium to the S&P, his intrinsic range is $600-$650 (above today's price), and his DCF at $580 roughly matches current price. Meanwhile, the four unabashed Bulls present a rare convergence: a 15-point The Scuttlebutt Growth Investor checklist sweep, a 30% The Intrinsic-Value Modeler upside, a 5-year-low multiple against all-time-high fundamentals, and a 9/10 fundamental score. The weight of the evidence sits with the Bulls — but the conviction is MED, not HIGH, because The Quality Rationalist and The Forensic Skeptic are right that this is 'fair price for a wonderful business,' not 'cheap.'
Key levels
Key levels · MA
USD · as of 2026-08-15Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Mastercard past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: Mastercard's two-sided network, reinforced by the 'Tokenization for All' initiative that deepens switching costs for both merchants and consumers, creates a toll-bridge moat that is nearly impossible to disrupt, with operating margins near 60% and FCF conversion above 47% confirming the economics are real and widening. Conviction: Conviction is held back because at 31x trailing earnings the margin of safety is thin: a stumble in cross-border volumes or a macro shock leaves little room for error, and the 93% analyst buy-rating with sub-1% short interest signals that everyone is already in the boat.
The Intrinsic-Value ModelerValuation/DCF🟢 BullishMed
Signal: The market is pricing in a revenue-growth deceleration far steeper than warranted: value-added services, now 37% of revenue and carrying structurally higher margins than core switching, create a mix-shift tailwind that pushes my base-case intrinsic value to $745, a 31% discount to today's price. Conviction: Conviction strengthens because the disconnect rests on multiple independent pillars: a 5-year low P/E against all-time-high margins, a self-reinforcing network moat no competitor can replicate from scratch, and services revenue that acts as a hidden margin accelerant most consensus models underweight.
The GARP OperatorGrowth (GARP)🟢 BullishHigh
Signal: Mastercard screens as a Stalwart with Fast-Grower characteristics: the trailing P/E of 31x sits below the three-year average of 38x while operating margins have climbed from 54% to 60% over five years, meaning you are buying a better company at a cheaper price for the first time in half a decade. Conviction: Confidence runs high because the bull case does not depend on a single heroic assumption: the PEG of 1.61 is reasonable for a wide-moat compounder, the services pivot at 37% of revenue adds a hidden-asset dimension, and management has shrunk the share count by over 100 million shares in five years without adding leverage risk.
The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishHigh
Signal: This is a 15-for-15 on the The Scuttlebutt Growth Investor checklist, a rare perfect score driven by a two-sided network moat that no rational entrant can replicate, services revenue growing faster than the core business and lifting margins, and management that has compounded per-share value through disciplined buybacks without a single quarter of deterioration across any qualitative criterion. Conviction: Conviction is held back by one unresolved dependency: the absence of any insider open-market purchases in the last 90 days, combined with the CEO's post-earnings 10b5-1 sale, provides no affirmative signal from management that the shares are undervalued at current levels despite the checklist sweep.
The Quality RationalistMental Models/Quality🟢 BullishMed
Signal: Mastercard is a toll booth on a growing road: the combination of a 5-year low P/E quartile, 46% net margins matched by 47% FCF margins with zero accrual games, and a 93.8% ROIC that requires almost no incremental capital to grow — all while the stock sulks at the bottom of its historical valuation band — is the The Quality Rationalist bargain appearing for the first time in years. Conviction: Conviction stays below full throttle because the current price is merely fair rather than cheap: a 15–20% drawdown on macro noise to the $460–$480 range, compressing the multiple toward 25x, would transform this from a reasonable purchase into an opportunity where I would be greedy.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The business quality is genuine but the entry price is not: my DCF at 7% growth lands at $580, essentially today's price, while a normalized 25x P/E on $4.50 in earnings points to $450 — meaning the current quote already embeds above-average growth in perpetuity with no margin for multiple contraction or a consensus unwind. Conviction: Conviction in the neutral stance strengthens because three independent warning lights are flashing together: 93% analyst unanimity leaves narrow exits, the monthly MACD bearish crossover suggests fading momentum at a mature uptrend's top, and the CEO's post-earnings share sale — however routine — aligns with zero insider purchases across the last quarter.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six panelists agree Mastercard's business quality is exceptional: a two-sided network moat with 46% net margins, 47% FCF conversion, and structural growth from global cash-to-digital migration.
- All six agree the tokenization push and value-added services (37% of revenue) are widening the moat, not just maintaining it.
- All six concur that interchange-fee regulation is the single existential threat, though none see it as an imminent catalyst.
- All six recognize that the current trailing P/E of 31x sits at the low end of Mastercard's own five-year range, creating a valuation entry that has been rare for this name.
The real debate
- The Intrinsic-Value Modeler sees a 31% discount to intrinsic value and calls it a genuine margin of safety, while The Forensic Skeptic applies a normalized 25x P/E and argues the stock is at best fairly priced with downside to $450 — the entire debate turns on whether Mastercard's premium multiple is structural or cyclical.
- The Quality Rationalist and The Scuttlebutt Growth Investor treat the monthly MACD bearish crossover as irrelevant noise for a decade-long compounder, while The Forensic Skeptic and The Moat Compounder read it as a warning that patience will be rewarded with a better entry.
- The GARP Operator and The Scuttlebutt Growth Investor view the 10b5-1 insider sales as mechanical non-events, while The Forensic Skeptic flags the absence of any open-market insider buying as a signal that management does not see deep undervaluation here.
The question it comes down to: Is Mastercard's current multiple — the low end of its own history but still a premium to the broad market — a structural discount that reflects permanent regulatory overhang, or a cyclical compression that will mean-revert higher as services revenue crosses 40% of the mix and the moat proves durable against alternative payment rails?
The bottom line
- Trigger to confirm the breakout: A weekly close above the all-time high at $601 would resolve the monthly MACD bearish crossover and signal that the uptrend is still in its early innings, not its late ones.
- Accumulation zone to watch: A pullback to the $530–$550 band, where the monthly EMA20 and weekly EMA50 cluster, compresses the trailing P/E toward 25–27x and would raise conviction across the panel materially.
- Risk level to monitor: A weekly close below $529.60 breaks both the monthly EMA20 and the weekly EMA50 simultaneously, confirming distribution and flipping the technical picture bearish regardless of fundamentals.
- Next catalyst: Q3 earnings in late October 2026 will test whether value-added services can cross 40% of total revenue — a threshold that would validate the margin-expansion thesis and potentially re-rate the multiple upward.
- Existential risk on the horizon: Any material interchange-fee legislation in the US or EU that impairs forward revenue guidance would invalidate the bull case across all six frameworks overnight, since the entire thesis rests on the toll-booth economics remaining intact.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in MA · MA verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated